Series B funds the shift from proven model to scaled machine. The metrics bar in 2026 is higher than it was in 2021. Here's what actually clears it.
Series B used to fund experiments. Post-2023, it funds proven engines. Investors want to see that adding a dollar of go-to-market spend produces predictable output — and that unit economics improve, not degrade, with scale.
$5-15M ARR, 2-3x YoY growth, NRR of 115%+, burn multiple under 2x, defined path to $50M ARR. Sales team scaled beyond founders. Multiple channels contributing to pipeline. Clean cohort retention curves at 12+ months.
$20-50M typical. $150-350M post-money valuation. Growth-stage lead (Insight, IVP, Bessemer growth arm, Meritech, TCV, General Catalyst). Board expands to 5 seats. Secondary component common — 5-15% of round often goes to founder/early-employee liquidity.
Investors run structured diligence with data-room analytics. Reference calls with 5-10 customers. Cohort analysis at monthly granularity. Sales rep productivity by tenure. Marketing attribution across channels. Any weakness surfaces — plan for that scrutiny.
Raising before efficiency metrics support scale. Optimizing for valuation over investor quality. Skipping the CFO hire (Series B is the point where FP&A becomes existential). Adding board members without alignment on strategy.
Investor directory · Fundraising library · Articles A–Z · Company funding database